Related references
Note: Only part of the references are listed.Atacicept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate Results of a Phase II, Randomized, Placebo-Controlled Trial
R. F. van Vollenhoven et al.
ARTHRITIS AND RHEUMATISM (2011)
Pharmacokinetics and Immunoglobulin Response of Subcutaneous and Intravenous Atacicept in Patients With Systemic Lupus Erythematosus
I. Nestorov et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Biological therapy for lupus nephritis-tribulations and trials
Rona M. Smith et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers
Thomas Doerner et al.
PHARMACOLOGY & THERAPEUTICS (2010)
B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin
Stacey R. Dillon et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis
C. Bracewell et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Treatment of rheumatoid arthritis: state of the art 2009
Ronald F. van Vollenhoven
NATURE REVIEWS RHEUMATOLOGY (2009)
Synovial tissues concentrate secreted APRIL
Cem Gabay et al.
ARTHRITIS RESEARCH & THERAPY (2009)
Induction of macrophage secretion of tumor necrosis factor a through Fcγ receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen
Cyril Clavel et al.
ARTHRITIS AND RHEUMATISM (2008)
Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2008)
Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis
Ivan Nestorov et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Cutting edge: The dependence of plasma cells and independence of memory B cells on BAFF and APRIL
Micah J. Benson et al.
JOURNAL OF IMMUNOLOGY (2008)
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts
Claudia Bossen et al.
BLOOD (2008)
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
R. M. Thurlings et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Atacicept in patients with rheumatoid arthritis
P. P. Tak et al.
ARTHRITIS AND RHEUMATISM (2008)
Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus
Maria Dall'Era et al.
ARTHRITIS AND RHEUMATISM (2007)
B cells in rheumatoid arthritis
Serena Bugatti et al.
AUTOIMMUNITY REVIEWS (2007)
Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
Alain Munafo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Intestinal bacteria trigger T cell-independent immunoglobulin A2 class switching by inducing epithelial-cell secretion of the cytokine APRIL
Bing He et al.
IMMUNITY (2007)
Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis
Shouvik Dass et al.
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
JCW Edwards et al.
NATURE REVIEWS IMMUNOLOGY (2006)
An APRIL to remember: novel TNF ligands as therapeutic targets
SR Dillon et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis
SM Tan et al.
ARTHRITIS AND RHEUMATISM (2003)
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases
V Roschke et al.
JOURNAL OF IMMUNOLOGY (2002)
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL
MB Litinskiy et al.
NATURE IMMUNOLOGY (2002)
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators
BL Hsu et al.
JOURNAL OF IMMUNOLOGY (2002)
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS
JA Gross et al.
IMMUNITY (2001)
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice
H Wang et al.
NATURE IMMUNOLOGY (2001)
BAFF mediates survival of peripheral immature B lymphocytes
M Batten et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response
RKG Do et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population
JS Thompson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI
SA Marsters et al.
CURRENT BIOLOGY (2000)
Share Paper
